Search results

Search:
in the keywords: third-generation anticonvulsant drugs

Sort By:

Limit search:

ADVANCES AND LIMITATIONS IN PHARMACOTHERAPY OF EPILEPSY

100%

Rapacz A.

Acta Poloniae Pharmaceutica - Drug Research

2018

vol. 75

issue 5

1069-1082

Epilepsy is a chronic neurologic disorder that affects about 0.7% of the population. Patients with epilepsy suffer from recurrent seizures, which can be focal or generalized in nature. The third-generation of anticonvulsant drugs includes lacosamide, rufinamide, vigabatrin, retigabine, perampanel, eslicarbazepine acetate, brivaracetam and stiripentol. Other compounds, such as ganaxolone, cannabidiol, selurampanel, and everolimus among others, with different mechanisms of action are currently in clinical development. Furthermore, numerous compounds or classes of compounds are investigated in preclinical studies. Nevertheless, about 30% of epilepsy patients suffer from uncontrolled seizures despite pharmacotherapy, including the third-generation of anticonvulsant drugs. Additionally, the occurrence of adverse drug effects is responsible for poor compliance as well as discontinuation of the therapy, in up to 25% of patients before having reached the effective dose amount. Neuropsychiatric undesirable effects, include depression, aggression, irritable mood, anxiety, mood instability, paranoid ideation, delusions, hallucinations. Moreover, suicidal ideation and behaviour have been reported in patients treated with anticonvulsant drugs.

Refine search results

1 Acta Poloniae Pharmaceutica - Drug Research

1 2018

1 Rapacz A.

Search results

ADVANCES AND LIMITATIONS IN PHARMACOTHERAPY OF EPILEPSY